<DOC>
	<DOCNO>NCT00002787</DOCNO>
	<brief_summary>The purpose trial test safety immune response four immunization vaccine make protein produce patient 's tumor . There guarantee promise procedure successful</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety multiple subcutaneous vaccination myeloma Id-KLH ( idiotype-keyhole limpet hemocyanin ) GM-CSF ( sargramostim ) post allogeneic transplant myeloma patient , GM-CSF +/- interleukin ( IL ) -2 ( aldesleukin ) post autologous transplant myeloma patient . II . To evaluate patient pre post bone marrow transplantation ( BMT ) evidence endogenous idiotype specific immune response . III . To characterize time course , specificity persistence antibody T cell immune response myeloma idiotype KLH induce myeloma Ig ( Id ) immunization . IV . To clone , expand characterize T cell specific tumor idiotype . V. Monitor myeloma involvement bone marrow serum paraprotein level follow vaccination . VI . Use store patient sample clone , expand , characterize T cell specific myeloma antigens idiotype identify antigen recognize used future study . OUTLINE : Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combine sargramostim subcutaneously ( SC ) week 0 , 2 , 6 , 10 sargramostim SC daily ( QD ) three day follow vaccine injection . Some patient also receive aldesleukin SC daily week 2-14 . After completion study treatment , patient follow every 3 month 1 year every 6 month 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>ELIGIBILITY FOR VACCINE PREPARATION : Patients must diagnosis multiple myeloma eligible Fred Hutchinson Cancer Research Center ( FHCRC ) treatment protocol use high dose therapy syngeneic , allogeneic autologous marrow stem cell transplantation Pretransplant serum available immunoglobulin A ( IgA ) , immunoglobulin D ( IgD ) , immunoglobulin E ( IgE ) , immunoglobulin G ( IgG ) , immunoglobulin M ( IgM ) monoclonal paraprotein level 1.5 grams/dl great identifiable serum protein electrophoresis ; eligibility patient pretransplant paraprotein level less 1.5 gm/dl evaluate individual basis determine whether purification idiotype feasible ELIGIBILITY FOR POSTTRANSPLANT IDIOTYPE VACCINATION : Successful isolation production autologous idiotype vaccine preBMT serum Greater 60 day post BMT Achievement partial remission great ( 75 % reduction serum paraprotein ) patient transplant relapse Stable absolute neutrophil count ( ANC ) &gt; 1000 Platelet count &gt; 50,000 require transfusion growth factor Red blood cell ( RBC ) supportable hematocrit ( Hct ) &gt; 25 less 2 unit pack red blood cell ( PRBC ) /week Treatment stable dose Interferon allow Karnofsky status &gt; 60 percent Immunosuppression : Off corticosteroid Either immunosuppressive medication stable/tapering dose cyclosporin FK506 Graftvshost disease require treatment corticosteroid Serum creatinine &gt; 3.0 Uncontrolled infection Disease progression Presence medical complication opinion investigator would result inability tolerate vaccination protocol Patients history serious adverse reaction GMCSF Patients history serious adverse reaction IL2 receive concurrent IL2 administration may receive IdKLH vaccine GMCSF</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>